Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B5HF
|
||||
| Former ID |
DNCL002837
|
||||
| Drug Name |
BI-135585
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 1 | [1] | ||
| Company |
Boehringer Ingelheim Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Corticosteroid 11-beta-dehydrogenase, isozyme 1 | Target Info | Modulator | [2] | |
| KEGG Pathway | Steroid hormone biosynthesis | ||||
| Metabolism of xenobiotics by cytochrome P450 | |||||
| Metabolic pathways | |||||
| Chemical carcinogenesis | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| FSH Signaling Pathway | |||||
| PathWhiz Pathway | Steroidogenesis | ||||
| Reactome | Glucocorticoid biosynthesis | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| Metabolism of steroid hormones and vitamin D | |||||
| Glucocorticoid & Mineralcorticoid Metabolism | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01282970) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes. U.S. National Institutes of Health. | ||||
| REF 2 | New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.